ArticleFrontiers in medicine2026

Cost-effectiveness analysis of pembrolizumab plus trastuzumab and chemotherapy as first-line treatment for HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Haoyu Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.